Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301
Benitec reported positive interim Phase 1b/2a results for BB-301 in OPMD-related dysphagia, with 100% of the nine treated patients formal responders to therapy. High-dose Cohort 2 showed greater improvements than low-dose Cohort 1 at three months, including 100% vs 67% meeting response criteria for improved throat emptying, with no serious adverse events to date.
Key figures
- Drug Name
- BB-301
- Phase Of Trial
- Phase 1b/2a
- Responder rate
- 100%
- Cohort1 patients
- 6
- Cohort2 patients
- 3
- Patients treated
- 9
- Pivotal study timing
- mid-2027
- Serious adverse events
- 0
- Opmd patient population
- 15000
- Cohort1 cwdt response 3mo
- 17%
- Cohort2 cwdt response 3mo
- 67%
- Cohort1 throat emptying response 3mo
- 67%
- Cohort2 throat emptying response 3mo
- 100%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.